<DOC>
	<DOCNO>NCT01328249</DOCNO>
	<brief_summary>The purpose study assess feasibility dose-dense doxorubicin cyclophosphamide follow eribulin mesylate adjuvant treatment early stage breast cancer .</brief_summary>
	<brief_title>Dose Dense Doxorubucin Cyclophosphamide Followed Eribulin Mesylate Adjuvant Treatment Early Stage Breast Cancer</brief_title>
	<detailed_description>This single-center , single-arm Phase II trial ass feasibility dose-dense adjuvant chemotherapy subject early stage ( I-III ) , HER-2 normal breast cancer . A total 80 adult subject enrol order 73 subject start eribulin portion adjuvant study regimen . After completion 4 cycle AC , subject begin 4 cycle eribulin mesylate 1.4 mg/m2 intravenously 2 5 minute Days 1 8 every 21 day cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Male female subject age great 18 year Histologically confirm Stage I III invasive breast cancer . Subjects may one synchronous primary breast tumor . Her2 normal determine fluorescence situ hybridization ( FISH ) 0 1+ immunohistochemistry ( IHC ) stain . Subject candidate chemotherapy adjuvant setting . Adjuvant therapy must begin within 84 day final surgical procedure breast cancer . Adequate cardiac function , define baseline LVEF great 50 % Multiple Gated Acquisition ( MUGA ) scan echocardiogram . ECOG performance status 0 1 . Adequate renal function evidence serum creatinine le 1.5 mg/dL calculate creatinine clearance great 40 mL/min per Cockcroft Gault formula . Adequate bone marrow function evidence ANC great 1.5 x 10^9/L , hemoglobin great 10.0 g/dL , platelet count great 100 x 10^9/L . Adequate liver function evidence bilirubin less 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less 3 x ULN . Females childbearing potential must negative urine betahuman chorionic gonadotropin serum pregnancy test within 2 week prior Cycle 1 , Day 1 . A urine pregnancy test repeat prior chemotherapy conduct within 72 hour start treatment . Female subject childbearing potential must agree abstinent use highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , intrauterine device ( IUD ) , vasectomized partner ) start least one menstrual cycle prior start study drug throughout entire study period 30 day ( longer appropriate ) last dose study drug . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male subject abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use , highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug throughout entire study period 30 day ( longer appropriate ) last dose study drug . Subjects partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Subjects willing able comply study protocol duration study provide write informed consent prior studyspecific screening procedure understand subject may withdraw consent time without prejudice . Exclusion Criteria Stage IV breast cancer . Prior chemotherapy , radiation therapy , immunotherapy , biotherapy current breast cancer . Nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc . ) would preclude study therapy drug . Subjects concurrently active second malignancy adequately treat nonmelanoma skin cancer situ cervical cancer . Subjects know positive human immunodeficiency virus ( HIV ) status . Pregnancy breast feed time study enrollment . Eligible subject reproductive potential ( sex ) must agree use adequate contraceptive method study therapy . Subjects know allergy hypersensitivity doxorubicin , cyclophosphamide , eribulin mesylate . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2-normal Stage I III invasive breast cancer</keyword>
</DOC>